{"name":"St Stephens Aids Trust","slug":"st-stephens-aids-trust","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Darunavir, Ritonavir and Rilpivirine","genericName":"Darunavir, Ritonavir and Rilpivirine","slug":"darunavir-ritonavir-and-rilpivirine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir","genericName":"Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir","slug":"dolutegravir-efavirenz-efavirenz-emtricitabine-tenofovir","indication":"HIV-1 infection (treatment and prevention)","status":"marketed"},{"name":"Eviplera®","genericName":"Eviplera®","slug":"eviplera","indication":"HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL","status":"marketed"},{"name":"Darunavir ritonavir","genericName":"Darunavir ritonavir","slug":"darunavir-ritonavir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Triumeq","genericName":"Triumeq","slug":"triumeq","indication":"Other","status":"marketed"},{"name":"Rezolsta","genericName":"Rezolsta","slug":"rezolsta","indication":"Other","status":"phase_1"},{"name":"TMC125 twice daily","genericName":"TMC125 twice daily","slug":"tmc125-twice-daily","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Tivicay","genericName":"Tivicay","slug":"tivicay","indication":"Human immunodeficiency virus infection","status":"marketed"}]}],"pipeline":[{"name":"Darunavir, Ritonavir and Rilpivirine","genericName":"Darunavir, Ritonavir and Rilpivirine","slug":"darunavir-ritonavir-and-rilpivirine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""},{"name":"Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir","genericName":"Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir","slug":"dolutegravir-efavirenz-efavirenz-emtricitabine-tenofovir","phase":"marketed","mechanism":"These are antiretroviral drugs that inhibit HIV replication through different mechanisms: dolutegravir blocks integrase, efavirenz inhibits reverse transcriptase, and the combination tablet inhibits both reverse transcriptase and blocks viral entry.","indications":["HIV-1 infection (treatment and prevention)","AIDS"],"catalyst":""},{"name":"Eviplera®","genericName":"Eviplera®","slug":"eviplera","phase":"marketed","mechanism":"Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.","indications":["HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL"],"catalyst":""},{"name":"Triumeq","genericName":"Triumeq","slug":"triumeq","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Darunavir ritonavir","genericName":"Darunavir ritonavir","slug":"darunavir-ritonavir","phase":"marketed","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Rezolsta","genericName":"Rezolsta","slug":"rezolsta","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TMC125 twice daily","genericName":"TMC125 twice daily","slug":"tmc125-twice-daily","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tivicay","genericName":"Tivicay","slug":"tivicay","phase":"marketed","mechanism":"Transmembrane protein 97, Integrase, Integrase","indications":["Human immunodeficiency virus infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9xdkZueHR4cWpoMC1hVk1VVXFobjFadl9jQTRWYW5LaFpMVWdYQ2Jad2JoYk15X3FxckY3WWM1YVJZM21mLUdrTmhQMmdfd0F2YUNRU0ZJVndIbEJTVE5J?oc=5","date":"2022-01-28","type":"pipeline","source":"Nature","summary":"Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC - Nature","headline":"Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQZWhnNVJIOVNkenZBbExhY2RSTS1DWFVoOUNMVVIyTGJrdzlGc2IwWG5hUGtkU2l3MjNMZnRWbDJQbFNjdC1wOXhqdkY3TmstWkNBaDB2alAzVUljT0l5bS1lTXI3eG1aRS1lVFItWkNPdHE2RHZGSTlHNkF2MnVsX09DclBZMTRwcmw3OFFDaGNGRDJiTkhZT0hLTmVOc1NNdHdfMdIBc0FVX3lxTE9wZ0I2VDJCN21oSXpFS1ZTdlJYNWl2c3lzdXo4aXotLW1vMlZtNFlSTU45ZVoyYl9kaVl3REl1aVZDWWlGbU9KZjZzM2FKZWRDZ0NrYWdFTkZraEVPdVJLOW1pMGowTnEyc1NJNXNsa1p3SGM?oc=5","date":"2018-10-29","type":"patent","source":"Life4me+","summary":"Effectiveness of generic drugs for Hepatitis C treatment has been proven - Life4me+","headline":"Effectiveness of generic drugs for Hepatitis C treatment has been proven - Life4me+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5Hb2RhTFpZaUc4ZTZwNnRLQjBMdjVzSWFIREtZeGlFa0xiaXJkTkhmblFERWpyOXZ6eUNMNjRlLVFHaGdqZWNra0x3aU9lTGZ1eWlEeEIwYjdBQWhZMkNfUXpyaUtNNjF0NXpRYVNpWEY?oc=5","date":"2018-08-22","type":"pipeline","source":"VICE","summary":"The Myth That PrEP Is Just For Gay Men is Hurting Women - VICE","headline":"The Myth That PrEP Is Just For Gay Men is Hurting Women","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOb21pTnFqbmJxTWY2cF9MQW8tUHRUbHBQN2JibGJ3X3hFZGZJb1NIcnFJemtIa3BlOTlmZVV5LXBQMll0RTVvY3drMll3LVJ0T1l3d0Yyd2RlLWkyOTBGUzlocmpWY2JQNkJKT0pZN3FZMUYzb19IM0tIaEhpQW5CLUZR?oc=5","date":"2017-08-17","type":"patent","source":"hepmag.com","summary":"Generic Hepatitis, HIV and TB Treatments Could Plunge to $90 Each - hepmag.com","headline":"Generic Hepatitis, HIV and TB Treatments Could Plunge to $90 Each","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPT2FvMklZVG1USGZibmVZT25fb1N1NzBOWW1pUUMzM0ptbUo0SlM5NF9TM29xQTR2WWYtcHc0N2czYUFQSmJYQzRKdE1vUXJJMUt4bHpkT2RPWlo2dmowX1hWLVB1T0NoakxCXy1TZjFYcEtsbWZyWk1RbVZpN3VXZUVkT2VZS3cyaExnLVFLNmtfSmZVdW1kVEluTFQzTlNmWGhubTZ1NUtmc1l5?oc=5","date":"2016-10-25","type":"pipeline","source":"Aidsmap","summary":"New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment - Aidsmap","headline":"New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNVWRMV2RDTmpkc3g0V1B0SzZmRkFVOWlZOGRaUlMxQURFT0ZKUHg4UXZiRVpTbTdwX0tSQVlZY1k0MW1SYlNSVFF5S29kMExlUDczelZMMl9GaEV5ZDVjaHFIcVc3VFplSTBaV213dEV3aFFDT2JodHNWZEZ6SU5lREFVT1prMkV5MEFNT2c1Q0w2Yzg?oc=5","date":"2013-12-09","type":"pipeline","source":"Aidsmap","summary":"Thirty years as an NHS consultant, by Professor Brian Gazzard - Aidsmap","headline":"Thirty years as an NHS consultant, by Professor Brian Gazzard","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":6,"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}